JOAQUIM PRADO PINTO DE MORAES FILHO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data(2022) MORAES-FILHO, Joaquim Prado P.; DOMINGUES, Gerson; GUEDES, Juliana Leite Soares; ZATERKA, SchliomaIntroduction: Although potassium-competitive acid blockers (P-CABs) prompted safety concerns when first developed, they ultimately proved to have a favourable safety profile.Aim: To assess the safety of vonoprazan in the management of gastroesophageal reflux disease (GERD), peptic ulcers, or gastroduodenal mucosal lesions induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).Material and methods: From March to June 2021, a literature search was conducted using Medline via PubMed, Cochrane library, Lilacs, SciELO, and Centre for Reviews and Dissemination (CRD) electronic databases. After applying the eligibility criteria, 10 studies were included in this review. Of these 10 articles, vonoprazan was used as initial therapy in 6 and as maintenance therapy in 4. Adverse event rates were similar for vonoprazan and proton-pump inhibitors (PPIs). Conclusions: Our findings suggest that vonoprazan is a safe option for the management of erosive oesophagitis, gastric/ peptic ulcers, or peptic ulcers induced by chronic use of aspirin or NSAIDs.
- Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review(2023) DOMINGUES, Gerson; CHINZON, Decio; MORAES-FILHO, Joaquim Prado P.; SENRA, Juliana Tosta; PERROTTI, Marcos; ZATERKA, SchliomaIntroduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency - ANVISA.Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fu-marate.Material and methods: A literature search was conducted through April-May 2021 using official databases with a combi-nation of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate.Results: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control - particularly at night - using currently available PPIs, this new drug class is promising.Conclusions: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.
- Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review(2022) CHINZON, Decio; MORAES-FILHO, Joaquim Prado P.; DOMINGUES, Gerson; GUEDES, Juliana Leite Soares; SANTOS, Claudia Yang; ZATERKA, SchliomaIntroduction: Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases' unmet needs. Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs. Material and methods: A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases. Results: We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials. Conclusions: Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin-or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.